Filgrastim biosimilar - Dong-A ST

Drug Profile

Filgrastim biosimilar - Dong-A ST

Alternative Names: DA 3030; Leucostim; Leukopoeitin - Dong-A ST; Leukostim®; rhG-CSF - Dong-A ST

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Immunostimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Marketed Neutropenia
  • Phase II Diabetic neuropathies

Most Recent Events

  • 05 May 2016 Biocad plans a phase I trial for Leucocytosis (In volunteers) in Russia (SC) (NCT02762799)
  • 01 May 2016 Dong-A ST completes a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
  • 01 Feb 2016 Dong-A ST initiates a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top